Spyre Therapeutics, Inc.

NasdaqGS:SYRE Stock Report

Market Cap: US$7.7b

Spyre Therapeutics Management

Management criteria checks 4/4

Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of 2.67 years. total yearly compensation is $6.71M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth $52.79M. The average tenure of the management team and the board of directors is 2.7 years and 3 years respectively.

Key information

Cameron Turtle

Chief executive officer

US$6.7m

Total compensation

CEO salary percentage9.91%
CEO tenure2.7yrs
CEO ownership0.7%
Management average tenure2.7yrs
Board average tenure3yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 17

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Summary Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts. SYRE's $757M cash position funds operations into H2 2028, supporting multiple clinical milestones and reducing near-term financing risk. Read the full article on Seeking Alpha
Analysis Article • Jul 15

Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Mar 04

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Summary Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis. Upcoming clinical trials in 2025 and 2026 are critical for validating Spyre's therapies and determining its potential to shift the treatment paradigm. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Spyre Therapeutics: Different Name, Same Tune

Summary Today, we take an in-depth look at Spyre Therapeutics, Inc., which has promising assets in early-stage development, including SPY001, SPY002, and SPY003. The company changed its name from Aeglea BioTherapeutics, Inc. late last year, and thanks to a recent capital raise, is extremely well funded. Analyst firms also appear optimistic around the company's developmental approach. An analysis of SYRE stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 01

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Summary Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033. The global Ulcerative Colitis market is expected to be $10.79 billion by 2030. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aeglea BioTherapeutics (NASDAQ:AGLE) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency. Shares of the micro-cap clinical-stage biotech soared 57.5% to $0.80 in postmarket trading. The application was submitted by AGLE's commercialization partner in Europe and Middle East, Immedica Pharma, AGLE said in a statement. Arginase 1 deficiency is a rare, inherited disorder in which there is complete or partial lack of the enzyme arginase in the liver and red blood cells. Aeglea (AGLE) earlier in Aug. reported a mixed set of Q2 results.
Seeking Alpha • Aug 04

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q2 GAAP EPS of -$0.27 (vs. -0.10 Y/Y)  beats by $0.04. Revenue of $0.63M (-95.4% Y/Y) misses by $0.08M. Shares +5.07% PM.

CEO Compensation Analysis

How has Cameron Turtle's remuneration changed compared to Spyre Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$149m

Dec 31 2025US$7mUS$665k

-US$127m

Sep 30 2025n/an/a

-US$118m

Jun 30 2025n/an/a

-US$162m

Mar 31 2025n/an/a

-US$159m

Dec 31 2024US$7mUS$625k

-US$150m

Sep 30 2024n/an/a

US$75m

Jun 30 2024n/an/a

US$88m

Mar 31 2024n/an/a

-US$103m

Dec 31 2023US$16mUS$273k

-US$95m

Compensation vs Market: Cameron's total compensation ($USD6.71M) is about average for companies of similar size in the US market ($USD8.38M).

Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.

CEO

Cameron Turtle (36 yo)

2.7yrs
Tenure
US$6,707,361
Compensation

Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...

Leadership Team

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Director2.7yrsUS$6.71m0.69%
$ 52.8m
Scott Burrows
Chief Financial Officer2.8yrsUS$2.19m0.035%
$ 2.7m
Heidy King-Jones
Chief Legal Officer & Corporate Secretary2.8yrsUS$2.19mno data
Sheldon Sloan
Chief Medical Officer1.7yrsUS$2.21m0%
$ 0
Janet Gunzner-Toste
Senior Vice President of Operationsno datano datano data
Brian Connolly
Chief Technical Officer2.6yrsno datano data
Eric McIntyre
Vice President of Finance & Investor Relationsno datano datano data
James Myers
Vice President of Quality & Complianceno datano datano data
Justin LaFountaine
Senior Vice President of Corporate Developmentno datano datano data
Melissa Cooper
Senior Vice President of Peopleno datano datano data
James Kastenmayer
Consultant3.1yrsUS$865.79kno data
Joshua Friedman
Senior Vice President of Clinical Development2.6yrsno datano data
2.7yrs
Average Tenure
49yo
Average Age

Experienced Management: SYRE's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Director2.6yrsUS$6.71m0.69%
$ 52.8m
Daniel Von Hoff
Member of Scientific Advisory Board9.8yrsno datano data
Matthew Vander Heiden
Member of Scientific Advisory Board9.8yrsno datano data
Keith Flaherty
Member of Scientific Advisory Board9.8yrsno datano data
Jeffrey Albers
Independent Chairman of the Board2.6yrsUS$348.68k0.032%
$ 2.4m
Arthur Frankel
Member of Scientific Advisory Board9.8yrsno datano data
Wayne Klohs
Member of Scientific Advisory Board9.8yrsno datano data
Tomas Kiselak
Independent Director3yrsUS$296.18k0.47%
$ 35.9m
Mark McKenna
Director2.3yrsUS$288.68k0%
$ 0
Laurie Stelzer
Independent Director2.6yrsUS$313.68k0%
$ 0
Michael Henderson
Independent Director3yrsUS$298.68k0.10%
$ 7.8m
Sandra Milligan
Independent Director2.1yrsUS$306.18k0%
$ 0
3.0yrs
Average Tenure
55yo
Average Age

Experienced Board: SYRE's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/21 06:09
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spyre Therapeutics, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Julian HarrisonBTIG